Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer.
Immune cell infiltration is a common feature of many human solid tumors. Innate and adaptative immune systems contribute to tumor immunosurveillance. We investigated whether tumors evade immune surveillance by inducing states of tolerance and/or through the inability of some immune subpopulations to effectively penetrate tumor nests. Immunohistochemistry and flow cytometry analysis were used to study the composition and distribution of immune subpopulations in samples of peripheral blood, tumor tissue (TT), adjacent tumor tissue (ATT), distant non-tumor tissue (DNTT), cancer nests, cancer stroma, and invasive margin in 61 non-small-cell lung cancer (NSCLC) patients. A significantly higher percentage of T and B cells and significantly lower percentage of NK cells were detected in TT than in DNTT. Memory T cells (CD4+CD45RO+, CD8+CD45RO+) and activated T cells (CD8+DR+) were more prevalent in TT. Alongside this immune activation, the percentage of T cells with immunosuppressive activity was higher in TT than in DNTT. B- cells were practically non-existent in tumor nests and were preferentially located in the invasive margin. The dominant NK cell phenotype in peripheral blood and DNTT was the cytotoxic phenotype (CD56+ CD16+), while the presence of these cells was significantly decreased in ATT and further decreased in TT. Finally, the immunologic response differed between adenocarcinoma and squamous cell carcinoma and according to the tumor differentiation grade. These findings on the infiltration of innate and adaptative immune cells into tumors contribute to a more complete picture of the immune reaction in NSCLC.
Department of Pneumology, San Cecilio University Hospital, Granada, Spain.
María
M
Del Mar Valenzuela-Membrives
Institute for Biomedical Research, Virgen de las Nieves University Hospital, Granada, Spain.
Francisco
F
Perea-García
Department of Thoracic Surgery, Virgen de las Nieves University Hospital, Granada, Spain.
Abel
A
Sanchez-Palencia
Institute for Biomedical Research, Virgen de las Nieves University Hospital, Granada, Spain.
Francisco
F
Ruiz-Cabello
Department of Pathology, School of Medicine, University of Granada, Granada, Spain.
Mercedes
M
Gómez-Morales
Department of Statistics and Operative Research, School of Medicine, University of Granada, Granada, Spain.
María Teresa
MT
Miranda-León
Department of Pathology, School of Medicine, University of Granada, Granada, Spain.
Inmaculada
I
Galindo-Angel
Department of Biochemistry and Molecular Biology, School of Medicine, University of Granada, Granada, Spain.
María Esther
ME
Fárez-Vidal
D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D005260:Female; D006801:Humans; D007156:Immunologic Memory; D008168:Lung / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D008875:Middle Aged
flow cytometry; immunohistochemistry; immunological response; lung cancer; lymphocyte subsets
Eur J Immunol. 2007 May;37(5):1161-4
17447232
Nat Commun. 2015 Nov 09;6:8819
26549640
Nat Med. 2002 Apr;8(4):358-65
11927941
Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72
18402523
Blood. 2010 Nov 11;116(19):3853-64
20696944
PLoS Pathog. 2015 Oct 20;11(10):e1005177
26485519
Int Immunopharmacol. 2014 Feb;18(2):255-61
24345703
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14757-64
26823801
Nat Rev Immunol. 2007 Sep;7(9):703-14
17717540
Oncol Rep. 2005 Nov;14(5):1269-73
16211295
J Exp Med. 2010 Sep 27;207(10):2065-72
20819928
Immunity. 2013 Jul 25;39(1):11-26
23890060
Methods Mol Biol. 2008;415:151-62
18370153
J Clin Invest. 2002 Dec;110(12):1823-30
12488432
J Clin Oncol. 2011 Feb 20;29(6):610-8
21245428
J Clin Invest. 2011 Sep;121(9):3609-22
21841316
Tuberc Respir Dis (Seoul). 2015 Oct;78(4):341-8
26508921
Eur J Immunol. 2009 Aug;39(8):2059-64
19637199
Nat Rev Immunol. 2007 May;7(5):329-39
17438573
Trends Immunol. 2003 Nov;24(11):603-9
14596885
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
16514137
Curr Opin Immunol. 2015 Apr;33:101-11
25728990
J Exp Med. 2010 Sep 27;207(10):2073-9
20819924
J Exp Med. 2006 Apr 17;203(4):1033-43
16606675
Curr Opin Immunol. 2010 Apr;22(2):231-7
20144856
Hum Immunol. 2006 Jan-Feb;67(1-2):1-12
16698419
Nature. 2005 Aug 4;436(7051):709-13
16079848
Science. 2011 Jan 7;331(6013):44-9
21212348
Cancer Res. 2013 Jun 15;73(12):3591-603
23633484
PLoS One. 2010 Aug 06;5(8):e11966
20700504
J Immunol. 1994 Oct 15;153(8):3574-83
7930580
Science. 2006 Sep 29;313(5795):1960-4
17008531
Respiration. 1987;51(3):161-9
3496638
Cancer Immunol Immunother. 2014 Oct;63(10):1073-80
24756420
Nat Immunol. 2008 May;9(5):503-10
18425107
Nat Rev Immunol. 2006 Apr;6(4):295-307
16557261
Science. 2015 Apr 3;348(6230):74-80
25838376
Arch Med Sci. 2013 Jun 20;9(3):555-60
23847682
Mayo Clin Proc. 2008 May;83(5):584-94
18452692
Adv Immunol. 2009;101:27-79
19231592
Trends Immunol. 2009 Apr;30(4):143-9
19282243
Eur J Immunol. 2008 Nov;38(11):2964-8
18979512
Med Oncol. 2012 Dec;29(4):2364-71
22307765
Lung Cancer. 2012 Jan;75(1):95-101
21719142
Exp Cell Res. 2013 Jul 1;319(11):1644-9
23499742
J Clin Oncol. 2016 Apr 10;34(11):1223-30
26834066
Oncoimmunology. 2013 Jul 1;2(7):e25443
24073382
J Clin Oncol. 2009 Dec 10;27(35):5944-51
19858404
Immunology. 2011 Sep;134(1):17-32
21711350
Nat Rev Cancer. 2012 Mar 15;12 (4):298-306
22419253
Clin Cancer Res. 2003 Feb;9(2):606-12
12576425
Cancer Immunol Immunother. 2011 Jun;60(6):819-27
21373990
Curr Opin Immunol. 2010 Apr;22(2):215-22
20207124
Acta Histochem. 2013 Mar;115(2):151-7
22749378
Clin Cancer Res. 2012 Jun 1;18(11):3022-9
22510350